Jason C Weatherald

Assistant Professor



University of Alberta, 2009

Contact information


Office: 403-943-4779


i. UGME - Course 3 January-March, 2019
ii. MED 440 - Applied Evidence Based Medicine, yearly
iii. MDSC 569 – Advanced Topics in Physiology


Dr. Jason Weatherald is a respirologist with the Southern Alberta Pulmonary Hypertension Program at the Peter Lougheed Centre. He completed his MD and internal medicine residency at the University of Alberta followed by respiratory medicine fellowship training at the University of Calgary. He completed a European Respiratory Society/Canadian Respiratory Society-funded research fellowship in pulmonary vascular disease at Le Kremlin-Bicêtre, France under the supervision of Prof. Marc Humbert and Prof. Olivier Sitbon. His research examines pathophysiology of pulmonary vascular disease, specifically gas exchange and pulmonary arterial hemodynamics during exercise. He has also published on risk stratification strategies in pulmonary arterial hypertension. As a recent Canadian Vascular Network/Bayer fellowship recipient, his current research involves wave intensity analysis to describe right ventricular-pulmonary arterial interaction in patients with pulmonary hypertension and chronic thromboembolic pulmonary hypertension.


i. Weatherald J, Boucly A, Launay D, et al. Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. European Respiratory Journal 2018;52:1800678

ii. Weatherald J, Huertas A, Boucly A, et al. Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. Chest 2018;154:872–881.

iii. Weatherald J, Boucly A, Sahay S, Humbert M, Sitbon O. The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints? American Journal of Respiratory and Critical Care Medicine 2018;197:860–868.

iv. Weatherald J, Boucly A, Chemla D, et al. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation 2018;137:693–704.

v. Weatherald J, Chaumais M-C, Savale L, J et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. European Respiratory Journal 2017;50:1700217.


i. PVRI Conference -Travel Grant Award for Best Clinical Abstracts 2019
ii. European Respiratory Journal Peer Reviewer Award 2017
iii. ACCP Pulmonary Vascular Net Work Outstanding Abstract – CHEST 2013
iv. Associate Dean’s Letter of Excellence for Undergraduate Teaching 2013, 2014
v. First Prize Poster – Medicine Research Day 2012 – University of Alberta
vi. E. Garner King Award for Excellence in Pulmonary Medicine 2011